15th Nov 2005 11:56
Credit Suisse First Boston (Europe)15 November 2005 FORM 8.1 DEALINGS BY OFFERORS, OFFEREE COMPANIES OR THEIR ASSOCIATES FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS (Rules 8.1(a) and (b)(i) of the City Code on Takeovers and Mergers) The below transactions have taken place to flatten pre-existing proprietary bookpositions. The Panel Executive has informed Credit Suisse First Boston (Europe)Ltd on an ex parte basis that such transactions are permitted and have no codeconsequences. 1. KEY INFORMATION Name of person dealing (Note 1) Credit Suisse First Boston (Europe) Ltd Company dealt in SkyePharma Plc Class of relevant security to which the Ordinary Sharesdealings being disclosed relate (Note 2) Date of dealing 14 November 2005 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevantsecurity dealt in (Note 3) Long Short Number (%) Number (%)(1) Relevant securities 0 0(2) Derivatives (other than options) 0 0(3) Options and agreements to purchase/sell 0 0Total (b) Interests and short positions in relevant securities of the company, otherthan the class dealt in (Note 3) Class of relevant security: Long Short Number (%) Number (%)(1) Relevant securities(2) Derivatives (other than options)(3) Options and agreements to purchase/sellTotal (c) Rights to subscribe (Note 3) Class of relevant security: Details 3. DEALINGS (Note 4) (a) Purchases and sales Purchase/sale Number of securities Price per unit (Note 5)Buy 10000 0.4975 Buy 9717 0.4975 Buy 30000 0.4975 Buy 50000 0.4975 Buy 283 0.4975 Buy 8217 0.4950 Buy 35000 0.4975 Buy 11783 0.4950 Buy 90000 0.4950 Buy 123479 0.4950 Buy 521 0.4950 Buy 34479 0.4950 Buy 90000 0.4975 Buy 38333 0.5000 Buy 30000 0.5000 Buy 21667 0.5000 Buy 85000 0.5000 Buy 25000 0.5025 Buy 15561 0.5025 Buy 9439 0.5025 Buy 1329 0.5050 Buy 48671 0.5050 Buy 25000 0.4950 Buy 30000 0.4900 Buy 11000 0.4900 Buy 9000 0.4900 Buy 12000 0.4900 Buy 12000 0.4900 Buy 1000 0.4900 Buy 16505 0.4975 Buy 28495 0.4975 Buy 8399 0.4975 Buy 10688 0.4975 Buy 23513 0.4975 Buy 12564 0.4975 Buy 27380 0.4975 Buy 10534 0.4975 Buy 8300 0.4975 Buy 2465 0.4975 Buy 26433 0.5000 Buy 19816 0.5000 Buy 26433 0.5000 Buy 20000 0.5000 Buy 3088 0.5000 Buy 30246 0.5000 Buy 24000 0.5000 Buy 37 0.5050 Buy 27768 0.5050 Buy 15155 0.5025 Buy 21604 0.5025 Buy 9695 0.5050 Buy 18838 0.5050 Buy 23671 0.5050 Buy 2583 0.5050 Buy 26329 0.5050 Buy 8200 0.5025 Buy 30718 0.5025 Buy 23715 0.5025 Buy 30224 0.5025 Buy 29896 0.5025 Buy 19669 0.5025 Buy 26324 0.5025 Buy 14223 0.5050 Buy 1484 0.5025 Buy 31512 0.5025 Buy 29582 0.5025 Buy 25211 0.5025 Buy 3880 0.5025 Buy 15000 0.5025 Buy 6733 0.5025 Buy 15000 0.5025 Buy 15565 0.5025 Buy 10435 0.5025 Buy 18626 0.5025 Buy 8016 0.5025 Buy 18784 0.5025 Buy 7216 0.5025 Buy 10000 0.5025 Buy 10505 0.5025 Buy 15495 0.5025 Buy 14461 0.5025 Buy 2324 0.5025 Buy 6429 0.5000 Buy 6016 0.4975 Buy 11364 0.4975 Buy 9123 0.4950 Buy 9877 0.4950 Buy 2609 0.4950 Buy 8800 0.4950 Buy 11576 0.4950 Buy 1587 0.4950 Buy 6432 0.4950 (b) Derivatives transactions (other than options) Product name, Long/short (Note Number of securities Price per unite.g. CFD 6) (Note 7) (Note 5) (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, e.g. Expiry Optionname,e.g. selling, securities price American, date money paid/call purchasing, to which European receivedoption varying etc. the option etc. per unit relates (Note 5) (Note 7) (ii) Exercising Product name, e.g. Number of securities Exercise price per unit (Note 5)call option (d) Other dealings (including new securities) (Note 4) Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5) 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. .............................................................................. None .............................................................................. Is a Supplemental Form 8 attached? (Note 9) NO Date of disclosure 15 November 2005 Contact name Jenny Lundquist Telephone number 020 7883 4332 Name of offeree/offeror with which associated SkyePharma Specify category and nature of associate status (Note Connected Party10) Notes The Notes on Form 8.1 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L